Procter & Gamble Company (PG)
Official siteCONSUMER DEFENSIVE • HOUSEHOLD & PERSONAL PRODUCTS • NYSE
Market Cap: $393.56B
Last updated: Nov 17, 2026 at 11:06 AM ET
Procter & Gamble Company (PG) Earnings: Report Dates and Results
Procter & Gamble Company (PG) is expected to report earnings on Jan 20, 2027. In the quarter ended Sep 30, 2026, Procter & Gamble Company reported EPS of $2.00, above the $1.89 estimate. It beat the EPS estimate in each of the last 15 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PG has an expected report date of Jan 20, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 3.2% below the $1.88 reported for the quarter ended Dec 31, 2025.
PG Earnings Call
The latest PG earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, PG beat 38, missed 1 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $23.28B, up 4.0% from $22.39B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $2.00 | $1.89 | $1.85 - $2.00 | +5.82% | Beat | +0.5% | 19 | 4 up, 1 down | Oct 22, 2026 | $23.28B |
| Jun 30, 2026 | $1.43 | $1.41 | $1.37 - $1.44 | +1.42% | Beat | -3.4% | 18 | 0 up, 2 down | Jul 29, 2026 | $21.20B |
| Mar 31, 2026 | $1.59 | $1.56 | $1.53 - $1.58 | +1.92% | Beat | +3.2% | 16 | 0 up, 8 down | Apr 24, 2026 | $21.23B |
| Dec 31, 2025 | $1.88 | $1.86 | $1.82 - $1.92 | +1.08% | Beat | 0.0% | 15 | 0 up, 8 down | Jan 22, 2026 | $22.21B |
| Sep 30, 2025 | $1.99 | $1.90 | $1.86 - $1.93 | +4.74% | Beat | +3.1% | 17 | 1 up, 9 down | Oct 24, 2025 | $22.39B |
| Jun 30, 2025 | $1.48 | $1.42 | $1.37 - $1.45 | +4.23% | Beat | +5.7% | 18 | 5 up, 5 down | Jul 29, 2025 | $20.89B |
| Mar 31, 2025 | $1.54 | $1.53 | $1.48 - $1.58 | +0.65% | Beat | +1.3% | 19 | 0 up, 14 down | Apr 24, 2025 | $19.78B |
| Dec 31, 2024 | $1.88 | $1.86 | $1.82 - $1.93 | +1.08% | Beat | +2.2% | 22 | 0 up, 12 down | Jan 22, 2025 | $21.88B |
| Sep 30, 2024 | $1.93 | $1.90 | $1.80 - $1.94 | +1.58% | Beat | +5.5% | 20 | 1 up, 2 down | Oct 18, 2024 | $21.74B |
| Jun 30, 2024 | $1.40 | $1.37 | $1.35 - $1.41 | +2.19% | Beat | +2.2% | 20 | 3 up, 0 down | Jul 30, 2024 | $20.53B |
| Mar 31, 2024 | $1.52 | $1.41 | $1.39 - $1.44 | +7.80% | Beat | +10.9% | 17 | 3 up, 2 down | Apr 19, 2024 | $20.20B |
| Dec 31, 2023 | $1.84 | $1.70 | $1.62 - $1.72 | +8.24% | Beat | +15.7% | 19 | 4 up, 1 down | Jan 23, 2024 | $21.44B |
| Sep 30, 2023 | $1.83 | $1.72 | $1.66 - $1.76 | +6.40% | Beat | +16.6% | 18 | 8 up, 1 down | Oct 18, 2023 | $21.87B |
| Jun 30, 2023 | $1.37 | $1.32 | N/A | +3.79% | Beat | +13.2% | 16 | 3 up, 0 down | Jul 28, 2023 | $20.55B |
| Mar 31, 2023 | $1.37 | $1.32 | $1.30 - $1.34 | +3.79% | Beat | +3.0% | 18 | 5 up, 4 down | Apr 21, 2023 | $20.07B |
| Dec 31, 2022 | $1.59 | $1.59 | $1.55 - $1.63 | 0.00% | In line | -4.2% | 19 | 6 up, 2 down | Jan 19, 2023 | $20.77B |
| Sep 30, 2022 | $1.57 | $1.55 | $1.46 - $1.59 | +1.29% | Beat | -2.5% | 17 | 1 up, 2 down | Oct 19, 2022 | $20.61B |
| Jun 30, 2022 | $1.21 | $1.23 | $1.19 - $1.26 | -1.63% | Miss | +7.1% | 19 | 0 up, 1 down | Jul 29, 2022 | $19.52B |
| Mar 31, 2022 | $1.33 | $1.29 | $1.25 - $1.35 | +3.10% | Beat | +5.6% | 19 | 3 up, 2 down | Apr 20, 2022 | $19.38B |
| Dec 31, 2021 | $1.66 | $1.65 | $1.59 - $1.69 | +0.61% | Beat | +1.2% | 18 | 0 up, 1 down | Jan 19, 2022 | $20.95B |
| Sep 30, 2021 | $1.61 | $1.59 | $1.54 - $1.64 | +1.26% | Beat | -1.2% | 17 | N/A | Oct 19, 2021 | $20.34B |
| Jun 30, 2021 | $1.13 | $1.09 | $1.04 - $1.11 | +3.67% | Beat | -2.6% | 18 | N/A | Jul 30, 2021 | $18.95B |
| Mar 31, 2021 | $1.26 | $1.19 | $1.14 - $1.22 | +5.88% | Beat | +7.7% | 17 | N/A | Apr 20, 2021 | $18.11B |
| Dec 31, 2020 | $1.64 | $1.51 | $1.38 - $1.58 | +8.61% | Beat | +15.5% | 18 | N/A | Jan 20, 2021 | $19.75B |
| Sep 30, 2020 | $1.63 | $1.42 | $1.29 - $1.45 | +14.79% | Beat | +19.0% | 17 | N/A | Oct 20, 2020 | $19.32B |
| Jun 30, 2020 | $1.16 | $1.01 | $0.94 - $1.11 | +14.85% | Beat | +5.5% | 18 | N/A | Jul 30, 2020 | $17.70B |
| Mar 31, 2020 | $1.17 | $1.13 | $1.06 - $1.27 | +3.54% | Beat | +10.4% | 17 | N/A | Apr 17, 2020 | $17.21B |
| Dec 31, 2019 | $1.42 | $1.37 | $1.31 - $1.41 | +3.65% | Beat | +13.6% | 17 | N/A | Jan 23, 2020 | $18.24B |
| Sep 30, 2019 | $1.37 | $1.24 | $1.18 - $1.30 | +10.48% | Beat | +22.3% | 18 | N/A | Oct 22, 2019 | $17.80B |
| Jun 30, 2019 | $1.10 | $1.05 | $1.02 - $1.10 | +4.76% | Beat | +17.0% | 20 | N/A | Jul 30, 2019 | $17.09B |
| Mar 31, 2019 | $1.06 | $1.04 | $1.01 - $1.08 | +1.92% | Beat | +6.0% | 21 | N/A | Apr 23, 2019 | $16.46B |
| Dec 31, 2018 | $1.25 | $1.21 | $1.17 - $1.24 | +3.31% | Beat | +5.0% | 20 | N/A | Jan 23, 2019 | $17.44B |
| Sep 30, 2018 | $1.12 | $1.09 | $1.04 - $1.13 | +2.75% | Beat | +2.8% | 19 | N/A | Oct 19, 2018 | $16.69B |
| Jun 30, 2018 | $0.94 | $0.90 | $0.86 - $0.93 | +4.44% | Beat | +10.6% | 19 | N/A | Jul 31, 2018 | $16.50B |
| Mar 31, 2018 | $1.00 | $0.98 | $0.94 - $1.04 | +2.04% | Beat | +4.2% | 20 | N/A | Apr 19, 2018 | $16.28B |
| Dec 31, 2017 | $1.19 | $1.14 | $1.11 - $1.16 | +4.39% | Beat | +10.2% | 20 | N/A | Jan 23, 2018 | $17.39B |
| Sep 30, 2017 | $1.09 | $1.08 | $1.04 - $1.10 | +0.93% | Beat | +5.8% | 20 | N/A | Oct 20, 2017 | $16.65B |
| Jun 30, 2017 | $0.85 | $0.78 | $0.74 - $0.82 | +8.97% | Beat | +7.6% | 19 | N/A | Jul 27, 2017 | $16.08B |
| Mar 31, 2017 | $0.96 | $0.94 | N/A | +2.13% | Beat | +11.6% | N/A | N/A | Apr 26, 2017 | $15.61B |
| Dec 31, 2016 | $1.08 | $1.06 | N/A | +1.89% | Beat | +3.8% | N/A | N/A | Jan 20, 2017 | $16.86B |
Annual EPS
EPS for the fiscal year ended Jun 30, 2026 was $6.89, up 0.9% from the year before. It was $3.92 for the year ended Jun 30, 2017, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Jun 30, 2026 | $6.89 | +0.9% |
| Jun 30, 2025 | $6.83 | +3.6% |
| Jun 30, 2024 | $6.59 | +11.7% |
| Jun 30, 2023 | $5.90 | +1.5% |
| Jun 30, 2022 | $5.81 | +2.7% |
| Jun 30, 2021 | $5.66 | +10.5% |
| Jun 30, 2020 | $5.12 | +13.0% |
| Jun 30, 2019 | $4.53 | +7.3% |
| Jun 30, 2018 | $4.22 | +7.7% |
| Jun 30, 2017 | $3.92 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,500 words across 18 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,547 | 18 | |
| 2026Q2 | Jun 30, 2026 | 11,529 | 19 | |
| 2026Q1 | Mar 31, 2026 | 8,133 | 15 | |
| 2025Q4 | Dec 31, 2025 | 9,876 | 18 | |
| 2025Q3 | Sep 30, 2025 | 9,601 | 18 | |
| 2025Q2 | Jun 30, 2025 | 10,167 | 21 | |
| 2025Q1 | Mar 31, 2025 | 8,919 | 19 | |
| 2024Q4 | Dec 31, 2024 | 10,961 | 18 |
2026Q3 Earnings Call
Opening remarks
Andre Schulten CFO Good morning, everyone. Joining me on the call today are John Chevalier and Keri Cohen, our Senior Vice President of Investor Relations. I will start with an overview of results for the third quarter of fiscal '26 and then discuss our progress on near-term business interventions and longer-term transformation efforts. I'll close with guidance for fiscal '26 and then we'll take your questions. As we expected, we saw a solid acceleration in top line results in our fiscal third quarter. Bottom line results reflect the strength of the top line progress with partial offsets from incremental investments in the business and energy cost impacts from the conflict in the Middle East. Taken together, we remain on track to deliver within our guidance ranges for the fiscal year. Organic sales increased more than 3% versus the prior year. Volume increased 2 points, pricing was up 1 point and mix was flat for the quarter. We delivered broad-based growth across the business with each of our 10 product categories growing organic sales. Skin and Personal Care grew organic sales high single digits. Hair Care, Family Care and Home Care grew mid-single, Personal Health Care, Oral Care, Fabric Care, Baby Care, Feminine Care and Grooming each grew low single digits. Growth was also broad-based geographically with each of our 7 regions growing organic sales. Focus markets were up 3%. Organic sales in North America grew 4%. Volume was up 3 points, driven by improved consumption and trade inventory dynamics. We saw a benefit from base period trade inventory destocking and a modest help from a current period trade inventory increase late in the quarter, driven by Easter timing. Price/mix added a point of growth. The Europe region was up 2%, led by enterprise markets being up 6% and modest growth in focus markets, led by the U.K., Italy and Spain. Greater China organic sales grew 3%, continued growth in what remains a challenging consumer environment, Pampers and SK-II led the growth, each up double digits. Enterprise markets in aggregate grew 5% for the quarter. Latin America organic sales were up 5%, with Mexico and Brazil each up high single digits. Organic sales in Asia Pacific, Middle East, Africa enterprise region was up 4%. Global aggregate market share improved to in line with prior year with positive trends through the quarter. 26 of our top 50 category country combinations held or grew share for the quarter. On the bottom line, core earnings per share came in at $1.59, up 3% versus prior year on a currency-neutral basis, core EPS was in line with prior year.
Frequently Asked Questions About PG
When is Procter & Gamble Company's next earnings date?
Procter & Gamble Company's next earnings report is expected for Jan 20, 2027.
Did PG beat earnings estimates last quarter?
Yes. Procter & Gamble Company reported EPS of $2.00 for the quarter ended Sep 30, 2026, above the $1.89 estimate, a 5.82% surprise.
What EPS do analysts expect from PG next quarter?
The consensus EPS estimate for Procter & Gamble Company for the quarter ending Dec 31, 2026 is $1.82 from 20 analysts, with estimates from $1.71 to $1.89.
How often does PG beat earnings estimates?
Procter & Gamble Company beat the EPS estimate in each of the last 15 quarters, with an average surprise of +3.65%.
PG pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors